Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Lymphatic Diseases × blinatumomab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Leukemia 3 Recurrence 2 Lymphoproliferative Disorders 2 Burkitt Lymphoma 2 Neoplasms 1 Neoplasm, Residual 1 Lymphatic Diseases 1 Immunoproliferative Disorders 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01207388 2020-02-10

BLAST

Amgen Research (Munich) GmbH

Phase 2 Completed

116 enrolled 23 charts 1 FDA

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡